ArticleScientific reports2025
Identification of transarterial chemoembolization candidates in advanced hepatocellular carcinoma patients classified solely by performance status 1: a multicenter retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The Barcelona Clinic Liver Cancer (BCLC) advanced stage of hepatocellular carcinoma (HCC) includes a heterogeneous population, and new patient-tailored therapeutic indications are needed. Emerging evidence suggest that patients in this stage with mild tumor-related symptoms may benefit from more aggressive treatments including transarterial chemoembolization (TACE) and obtain better outcomes. This study aimed to investigate the effects of TACE on HCC patients with mild tumor-related symptoms and risk-stratify them for selecting potential candidates for TACE. We retrospectively collected data from 745 patients with liver-confined HCC undergoing TACE at 15 different centers from January 2015 to November 2022. The prognostic abilities of performance status (PS score of 0 vs. 1) were separately evaluated in high- and low-risk groups using the Hepatoma Arterial-embolization Prognostic (HAP) scoring model and its variants. PS1 remained an independent prognostic factor for overall survival (OS) in the whole cohort (P = 0.035). Interestingly, it lost its prognostic value for patients in low-risk groups (grade A + B) in all the four HAP models. This population with PS1 alone achieved similar OS to their counterparts with PS0. Risk stratification based on HAP scoring models could discriminate potential candidates from HCC patients in BCLC-C stage with PS1 alone. These patients could be classified into BCLC-B stage and benefit from TACE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.